Lawrence Helson
24Patents
11h-index
20Co-inventors
75Inventor score
Filing activity: Jan 29, 1993 → Jun 5, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6667346B2 | Method for protecting cells and tissues from ionizing radiation toxicity with &agr;, &bgr; unsaturated aryl sulfones | Human Necessities | 42 | Expired |
| US8753674B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | Emerging Cross-Sectional Technologies | 27 | Active |
| US9682041B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | Emerging Cross-Sectional Technologies | 19 | Active |
| US10349884B2 | Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel | Human Necessities | 15 | Active |
| US10258691B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies | Physics | 15 | Active |
| US10357458B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | Emerging Cross-Sectional Technologies | 15 | Active |
| US10238602B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies | Physics | 15 | Active |
| US10117881B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies | Physics | 15 | Active |
| US8747890B2 | Intravenous infusion of curcumin and a calcium channel blocker | Human Necessities | 14 | Active |
| US10449193B2 | Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies | Physics | 13 | Active |
| US9138411B2 | Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy | Human Necessities | 12 | Active |
| US5696153A | Therapeutic regimen for treating patients | Human Necessities | 10 | Expired |
| US10532045B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | Human Necessities | 6 | Active |
| US10617639B2 | Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current | Emerging Cross-Sectional Technologies | 5 | Active |
| US8784881B2 | Liposomal curcumin for treatment of diseases | Human Necessities | 3 | Active |
| US5688517A | Method for assessing sensitivity of tumor cells to cephalomannine and 10-deacetyltaxol | Emerging Cross-Sectional Technologies | 3 | Expired |
| US10485768B2 | Treatment for glioblastoma | Human Necessities | 2 | Active |
| US7981928B2 | Chemotherapy method using x-rays | Human Necessities | 1 | Expired |
| US10004687B2 | Liposomal curcumin for treatment of diseases | Human Necessities | 1 | Active |
| US11806401B2 | Prevention of drug-induced atrio-ventricular block | Human Necessities | 0 | Active |
| US9393198B2 | Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders | Human Necessities | 0 | Active |
| US10739353B2 | Suppression of cytokine release and cytokine storm | Emerging Cross-Sectional Technologies | 0 | Active |
| US9170257B2 | Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin | Physics | 0 | Active |
| US12004868B2 | Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.